Solventum Receives FDA Clearance For Combined Use Of Restrata Synthetic Electrospun Fiber Matrix, Solventum V.A.C. Therapy
Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber
Solventum got permission from the FDA to use two wound care products together. This means doctors can now combine these tools, which shows the company is growing its offerings.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.